108 related articles for article (PubMed ID: 9464335)
1. [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Nakabayashi T; Nakai Y; Kurita Y; Fukuoka M; Onoshi T; Ogura T; Sakuma A; Niitani H; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):97-109. PubMed ID: 9464335
[TBL] [Abstract][Full Text] [Related]
2. [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Ogura T; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):89-96. PubMed ID: 9464334
[TBL] [Abstract][Full Text] [Related]
3. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
[TBL] [Abstract][Full Text] [Related]
4. [Prophylactic effect of ulinastatin on cisplatin-induced renal disorders in lung cancer patients].
Horiguchi T; Kasahara J; Ogura K; Handa M; Hosoda H; Shakato A; Tachikawa S; Sato M; Suetsugu S; Umeda H
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):12-9. PubMed ID: 1625386
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
7. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
8. Nordihydroguaiaretic acid ameliorates cisplatin induced nephrotoxicity and potentiates its anti-tumor activity in DMBA induced breast cancer in female Sprague-Dawley rats.
Mundhe NA; Kumar P; Ahmed S; Jamdade V; Mundhe S; Lahkar M
Int Immunopharmacol; 2015 Sep; 28(1):634-42. PubMed ID: 26247680
[TBL] [Abstract][Full Text] [Related]
9. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
10. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
12. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
13. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
16. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
17. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
18. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
20. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
